Breast cancer is the second-leading cause of cancer-related death for women in the United States.1 It is estimated that 10% of these breast cancer diagnoses are attributed to pathogenic variants.2 More than 50% of these pathogenic variants are secondary to high penetrance genes, such as BRCA1 and BRCA2, which confer a 50–85% lifetime likelihood of developing breast cancer.2,3 Knowledge of this risk is imperative, because it alters surveillance, surgical interventions, and therapeutic recommendations for patients and their families. The gene discussed is BRCA2; the disease is breast carcinoma.